Sean P. Nolan's most recent trade in Ventas Inc was a trade of 2,047 Common Stock done at an average price of $90.3 . Disclosure was reported to the exchange on May 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ventas | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 90.35 per share. | 13 May 2026 | 2,047 | 26,181 (0%) | 0% | 90.3 | 184,946 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 23 Jan 2026 | 136,789 | 2,949,569 | - | 4.8 | 649,748 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.61 per share. | 23 Jan 2026 | 41,312 | 2,908,257 | - | 4.6 | 190,448 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 1,008,000 | 3,086,358 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 648,000 | 648,000 | - | - | Employee Stock Option (right to buy) | |
| Ventas | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 64.18 per share. | 13 May 2025 | 2,882 | 24,134 (0%) | 0% | 64.2 | 184,967 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 892,500 | 2,078,358 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 892,500 | 892,500 | - | - | Employee Stock Option (right to buy) | |
| Ventas | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 47.96 per share. | 14 May 2024 | 3,648 | 21,252 (0%) | 0% | 48.0 | 174,958 | Common Stock |
| Taysha Gene Therapies Inc | P. Sean Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,184,688 | 1,185,858 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | P. Sean Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,184,688 | 1,184,688 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean Nolan P. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 466,550 | 466,550 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 16 Aug 2023 | 444,444 | 1,535,545 | - | 0.9 | 400,000 | Common Stock |
| Ventas | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 45.63 per share. | 16 May 2023 | 3,835 | 17,604 (0%) | 0% | 45.6 | 174,991 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 1,106,131 | 1,106,131 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Ventas | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 57.25 per share. | 27 Apr 2022 | 3,056 | 13,769 (0%) | 0% | 57.3 | 174,956 | Common Stock |